Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWN: Continuation of certolizumab pegol with or without methotrexate in rheumatoid arthritis
jRCTs071190001Completed
- Sponsor
- UCB
- Start
- Aug 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA) (3 arms), sponsored by UCB. Primary endpoint: Maintenance of low disease activity (SDAI < 11). Started Aug 2019; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs071190001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190001.